[FONT="]-SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation-[/FONT][FONT="]-Vertex's third medicine approved to treat the underlying cause of CF in eligible patients in this age range-[/FONT]
https://investors.vrtx.com/press-releases